- Open Access
IL-6 expression predicts treatment response and outcome in squamous cell carcinoma of the esophagus
- Miao-Fen Chen†1, 2Email author,
- Ping-Tsung Chen†3, 4,
- Ming Shian Lu5,
- Paul Yang Lin6,
- Wen-Cheng Chen1, 2 and
- Kuan-Der Lee2, 3
© Chen et al.; licensee BioMed Central Ltd. 2013
- Received: 7 November 2012
- Accepted: 24 March 2013
- Published: 5 April 2013
The identification of potential tumor markers can improve therapeutic planning and patient management. The aim of this study was to highlight the significance of IL-6 in esophageal squamous cell carcinoma (SCC).
We retrospectively analyzed the clinical outcomes of 173 patients with esophageal SCC, and examined the correlation between IL-6 levels and clinical outcomes in esophageal cancer patients. Furthermore, the human esophageal SCC cell line CE81T was selected for cellular and animal experiments to investigate changes in tumor behavior and treatment response after manipulation of IL-6 expression.
In clinical outcome analysis, positive IL-6 staining and poor treatment response was significantly associated with shorter survival. Furthermore, the frequency of IL-6 immunoreactivity was significantly higher in esophageal cancer specimens than in non-malignant epithelium, and this staining was positively linked to the development of distant metastasis (p = 0.0003) and lower treatment response rates (p = 0.0001).By ELISA analysis, IL-6 serum levels were significantly elevated in patients developing disease failure.When IL-6 expression was inhibited, aggressive tumor behavior and radiation resistance could be overcome in vitro and in vivo. The underlying changes included increased cell death, less epithelial-mesenchymal transition and attenuated STAT3 activation. IL-6 inhibition was also associated with attenuated angiogenesis in tumor-bearing mice.
IL-6 was significantly associated with poor prognosis in patients with esophageal cancer. Targeting this cytokine could be a promising strategy for treatment of esophageal cancer, as evidenced by inhibition of aggressive tumor behavior and treatment resistance.
- IL-6, Esophageal squamous cell carcinoma
Esophageal cancer, an aggressive upper gastrointestinal malignancy, generally presents as a locally advanced disease and requires a multimodal concept. Despite improvements in its detection and management, the prognosis in patients with esophageal cancer remains poor, with a 5-year survival of 15–34% [1, 2]. Most patients who undergo curative treatment for esophageal cancer will eventually relapse and die as a result of their disease. Neoadjuvant chemoradiotherapy (CCRT) can increase the chance of R0 resection, and responders will have a survival benefit . Patient selection is important to guide multidisciplinary therapy. The identification of potential molecular markers to predict response to CCRT and recurrence is important for the effective management and prognosis of esophageal cancer.
Proinflammatory cytokine may contribute to tumor progression by stimulating angiogenesis, invasion and metastasis [4, 5] IL-6 is a pleiotropic cytokine that is capable of modulating diverse cell functions such as inflammatory reactions, and is a major activator of the JAK/STAT3 and PI3K/AKT signaling pathways . IL-6 signaling has been implicated in the regulation of tumor growth and metastatic spread in different cancers [7–9]. Moreover, increased IL-6 serum levels were reported to be associated with metastasis and poor prognosis in prostate, ovarian and gastrointestinal cancers [10–12]. Although evidence suggests that IL-6 is a critical factor in a variety of malignancies [11, 13, 14], how IL-6 modulates the biological activities of esophageal carcinoma cells and how it is associated with the prognosis of esophageal cancer remains unclear. There are two distinct histological types of esophageal cancer: squamous cell carcinoma (SCC) and adenocarcinoma. There are marked differences between these carcinomas in incidence, natural history and treatment outcomes . The majority of esophageal SCC cases occur in Asia, with the predominant type in Taiwan being SCC . We therefore investigated the role of IL-6 in esophageal SCC in vitro and in vivo, and examined the correlation between IL-6 levels and clinical outcomes in esophageal cancer patients.
The Institutional Review Board of Chang Gung Memorial Hospital approved the present study (Permit Number: 96-1693B). The written consents were signed by the patients for their specimen and information to be stored in the hospital and used for research. Patients who did not comply with the treatment regimen and those who received surgery alone for early-stage esophageal cancer were excluded from the study. A total of 173 patients with esophageal SCC who completed curative treatment were enrolled in the study. The curative treatment for esophageal cancer included neoadjuvant CCRT combined with surgery or definitive CCRT according to the guidelines proposed by oncology team at our hospital. On completion of neoadjuvant CCRT, patients underwent a repeat CT scan and endoscopic examination to determine the response to treatment. If the tumor was considered resectable, patients underwent surgery for the residual tumor. Pathologic complete response (CR) was defined as absence of residual invasive tumor in the surgical specimen in patients undergoing surgical intervention. For patients who refused surgery or in whom it was contraindicated, a second round of CCRT was administered, comprising two courses of chemotherapy and radiotherapy of a total of 60–63 Gy. Specimens collected from the 173 patients at diagnosis were subjected to immunochemical analysis. The main end points were overall survival (OS), disease-free survival (DFS) and response to neoadjuvant therapy. Survival probability was analyzed statistically using the Kaplan–Meier method. The significance of between-group differences was assessed using the log-rank test. Multivariate analyses were performed using a Cox regression model for survival.
Immunohistochemical staining (IHC)
Formalin-fixed, paraffin-embedded tissues from 173 patients with esophageal cancer were subjected to IHC staining. Dissected esophageal cancer specimens from 20 of these patients were converted into tissue microarray (TMA) blocks using an AutoTiss 1000 arrayer (Ever BioTechnology, Canada). The TMA block contained esophageal SCCs and the adjacent non-malignant epithelium. The quality of the TMA slides was confirmed by the pathologist using hematoxylin- and eosin-stained slides. The IHC data for the specimens were assessed using the semi-quantitative immunoreactive score (IRS). The criterion for positive staining was an IRS score of ≥2. The details were described in Additional file 1: Supplementary methods.
Cell culture and reagents
The human esophageal cancer cell line CE81T, derived from a well-differentiated esophageal SCC, was obtained from the Bioresource Collection and Research Center (BCRC),and cultured in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum. The IL-6-neutralizing antibody, STAT3 siRNA and the JAK inhibitor AG490 were purchased from R&D Systems (Minneapolis, MN) and Sigma (St. Louis, MO), respectively. The IL-6-GFP silencing vector (human IL6 shRNA constructs in retroviral GFP vector) and GFP-control vector (Non-effective scrambled shRNA cassette in retroviral GFP vector) were purchased from Origene Technologies, Inc. (Rockville, MD). Transfection in CE81T was carried out by Lipofectamine™ 2000 (Invitrogen) according to the manufacturer’s instructions. Stable cancer cells were generated by transfecting CE81T cells with either the IL-6 silencing vectors or control vectors, followed by selection with puromycin for 4 weeks.
To measure cell growth, 1×104 cells per well were plated into 6-well dishes. At the indicated time-points, cells were trypsinized, collected and surviving cells counted using Trypan blue exclusion, from which the survival curves for CE81T transfectants ( wild type, with control vectors, and with IL-6 silencing vectors) were established.
To determine the in vitro effects of STAT3 siRNA, proteins were extracted from cells transfected with STAT3 siRNA for 72 h. To determine the in vitro effects of the JAK inhibitor and the anti-IL-6 antibody, proteins were extracted from cells incubated in the presence of 50 μM AG490 or 5 μg/ml IL-6 neutralizing antibodies for 24 h. The details were described in Additional file 1: Supplementary methods.
Immunofluorescence staining (IF) and Statistical analysis
The details were described in Additional file 1: Supplementary methods.
Enzyme-linked immunosorbent assay (ELISA) analysis of IL-6 level
We examined the serum level of IL-6 from 71 patients among subjects enrolled with esophageal cancer in the present study. For serum specimen, five milliliters of peripheral blood were drawn from each patient. Moreover, IL-6 levels in cellular supertnant and murine serum were tested. Levels of IL-6 in samples were analyzed using an IL-6 Quantikine ELISA Kit (R&D system). The details were described in Additional file 1: Supplementary methods.
This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals as promulgated by the Institutes of Laboratory Animal Resources, National Research Council, U.S.A. The protocol was approved by the Committee on the Ethics of Animal Experiments of Chang Gung Memorial Hospital (Permit Number: 2012080903). Eight-week-old male athymic nude mice were used and all animal experiments conformed to the protocols approved by the experimental animal committee of our hospital. CE81T cancer cell transfectants (1 × 106 per implantation, five animals per group) were subcutaneously implanted in the dorsal gluteal region. To determine in vivo radiosensitivity, local irradiation (15 Gy) was performed when the tumor volume reached 500 mm3. Radiosensitivity was indicated by a growth delay (i.e., the time required for the tumor to recover its previous volume after irradiation). Duplicate experiments were performed for growth delay analyses. The details were described in Additional file 1: Supplementary methods.
Level of IL-6 in esophageal SCC
Clinico-pathological characteristics of esophageal cancer patients for immunohistochemical investigation
No. of patients
IHC- IL-6 (+)
> = 56y/0
Response to Neoadjuvant Tx
Surgery s/p Neoadjuvant Tx
Local-regional Recurrence /persistent
Role of IL-6 in tumor growth
Role of IL-6 in tumor invasion and underlying mechanisms
Effects of circulating IL-6 on tumor aggressiveness
Significance of IL-6 expression stratified according to the occurrence of local- regional failure (LR) or distant metastasis (DM) in 71 patients
IL-6 serum level
> = mean
P = 0.001
P = 0.035
IL-6 correlates with treatment response in esophageal SCC
Significance of IL-6 expression stratified according to the complete response to neoadjuvant treatment in 55 patients with surgery resection
P = 0.052
Correlation between the IL-6 level and clinical outcome
Univariate analysis to determine factors associated with prognosis
P value for overall survival
P value for disease-free survival
Positive staining for IL-6
Positive staining for p-STAT3
Multivariate analysis to determine molecular markers associated with prognosis (OS) of patients
95% confidence interval
Recurrence and/or distant metastasis
Multivariate analysis to determine molecular markers associated with prognosis (DFS) of patients
95% confidence interval
Multivariate analysis to determine factors associated with prognosis (OS) of patients with definite CCRT treatment
95% confidence interval
Recurrence and/or distant metastasis
Multivariate analysis to determine factors associated with prognosis (OS) of patients with pre-op CCRT and surgery
95% confidence interval
Recurrence and/or distant metastasis
Understanding the molecular mechanisms underlying aggressive tumor growth in esophageal SCC is pivotal to identifying novel targets for pharmacological intervention. Furthermore, clinical data [2, 3, 23] suggest the need for markers that predict responses to neoadjuvant CCRT and help to identify patients at high risk of tumor recurrence and distant metastasis. However, no suitable markers have been identified to date. The inflammatory cytokine IL-6 contributes to the growth and progression of various malignancies, such as HNSCC, prostate cancer and gastrointestinal cancer, and acts as an autocrine growth factor and an anti-apoptotic factor for various stimuli, including anticancer agents [11, 24–27]. Moreover, the IL-6/STAT3 pathway is important for the development of inflammation-associated intestinal tumorigenesis. Similar to other series [11, 28], we found that IL-6 and IL-6R were detected in both esophageal cancer specimens and esophageal carcinoma cell lines. IL-6 expression was higher in esophageal cancer specimens compared with non-malignant tissues. Furthermore, positive staining for IL-6 was associated with higher tumor stage, higher rates of tumor recurrence and distant metastasis. To further investigate whether IL-6 was responsible for aggressive tumor growth in esophageal SCC, we suppressed IL-6 in esophageal cancer cells using a silencing vector. Data obtained from cell and xenograft tumor growth experiments revealed that inhibiting IL-6 resulted in slower tumor growth and reduced invasiveness. The transformation of an epithelial cell into a mesenchymal cell appears to be functionally relevant to the invasive characteristics of epithelial tumors, including esophageal cancer [19, 29, 30]. At the molecular marker level, EMT is characterized by the loss of E-cadherin and increased expression of invasion-related factors . In cell experiments, the IL-6 silencing vector induced both an increase in E-cadherin levels in esophageal cancer cells, and decreases in MMP-9 levels. Constitutive activation of STAT3 signaling has been reported to contribute to oncogenesis by promoting proliferation and EMT, and IL-6 is a major activator of JAK/STAT3 signaling [8, 32–34]. Therefore, we examined the links between STAT3 activation, IL-6 and EMT. When blocking STAT3 activation by STAT3 siRNA or JAK inhibitor, the decreases in EMT-related protein levels were comparable to those induced by IL-6 silencing vector. Furthermore, IHC data obtained from clinical samples demonstrated that IL-6 expression was significantly correlated with p-STAT3 staining. Therefore, it is likely that STAT3 activation plays a role in transmitting IL-6 signals to downstream targets that regulate EMT and invasiveness.
In the present study, IL-6 silencing vectors significantly decreased IL-6 levels seen in the supernatant of cell culture medium and the serum of mice bearing tumors. Moreover, in the clinic, IL-6 serum levels seem to be elevated in a subgroup of patients with local-regional failure or distant metastasis. We assume that circulating IL-6 plays an important role to stimulate tumor growth in vivo, besides direct action on malignant cells. Angiogenesis is one of the mechanisms that promote tumor progression, and CD31-mediated endothelial cell-cell interactions are involved in angiogenesis. Moreover, STAT3 activation has been reported to modulate the expression of genes that mediate angiogenesis; e.g., VEGF . Accordingly, the links between IL-6, angiogenesis, and promotion of cancer in tumor-bearing mice were further investigated using a xenograft tumor model. Our data from animal experiments demonstrated that IL-6 level positively linked with angiogenesis in addition to EMT. These findings indicated that the promotion of EMT changes and angiogenesis mediate the aggressive tumor growth noted in IL-6 expressing esophageal cancer, at least in part.
Radiotherapy is a well-established therapeutic modality in oncology. It provides survival benefits in several cancer types, including esophageal cancer. For esophageal SCC, treatment response is an independent prognostic factor. We demonstrated that positive IL-6 staining was significantly associated with a lower response rate after treatment in patients with esophageal SCC. As determined using clonogenic assays and delayed tumor growth, inhibition of IL-6 by transfection of an IL-6 silencing vector increased radiosensitivity. Extensive DNA damage caused by radiation and anti-cancer agents can result in cell death or sensitivity to clinical treatment if left unrepaired . Phosphorylated H2AX is an indicator of double-strand breaks, and its expression after irradiation correlates with treatment sensitivity . Our data demonstrate that inhibition of IL-6 was associated with increased radiation-induced DNA damage and increased cell death. Moreover, the data from xenograft tumors demonstrated that inhibition of IL-6 attenuated angiogenesis and decreased p-STAT3 activation after irradiation. The expression of angiogenic factors is suggested to have predictive value for treatment response and outcome in patients with esophageal cancer [38, 39]. Therefore, we suggest activation of STAT3 signaling and angiogenesis after irradiation was reported to be responsible for resistance to treatment and tumor regrowth after irradiation triggered by IL-6.
We further examined the predictive power of IL-6 for prognosis in esophageal SCC. Besides a lower response to treatment, enhanced expression of IL-6 was significantly associated with a higher clinical stage, a greater risk of distant metastasis and shorter survival. In a multivariate analysis, IL-6 retained predictive power for OS.
These findings indicate that IL-6-positive esophageal cancer provides a suitable microenvironment for the development of tumor growth and treatment resistance mediated by induction of angiogenesis, enhancement of cell mobility, and promotion of EMT. Our data support the emerging notion that IL-6 and p-STAT3 are clinically significant predictors, and suggest that IL-6 may represent a suitable target for esophageal SCC treatment.
The work was support by National Science Council, Taiwan. Grant 98-2314-B-182-038-MY2 (to M.F. Chen).
- Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE: Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009, 27: 5062-7. 10.1186/1476-4598-12-26View ArticlePubMedGoogle Scholar
- Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A: Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011, 12: 681-92. 10.1016/S1470-2045(11)70142-5View ArticlePubMedGoogle Scholar
- Pottgen C, Stuschke M: Radiotherapy versus surgery within multimodality protocols for esophageal cancer–a meta-analysis of the randomized trials. Cancer Treat Rev. 2012, 38: 599-604. 10.1016/j.ctrv.2011.10.005View ArticlePubMedGoogle Scholar
- Coussens LM, Werb Z: Inflammation and cancer. Nature. 2002, 420: 860-7. 10.1038/nature01322PubMed CentralView ArticlePubMedGoogle Scholar
- Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y: Cytokines in cancer immunity and immunotherapy. Immunol Rev. 2004, 202: 275-93. 10.1111/j.0105-2896.2004.00199.xView ArticlePubMedGoogle Scholar
- Schafer ZT, Brugge JS: IL-6 involvement in epithelial cancers. J Clin Invest. 2007, 117: 3660-3. 10.1172/JCI34237PubMed CentralView ArticlePubMedGoogle Scholar
- Akira S, Taga T, Kishimoto T: Interleukin-6 in biology and medicine. Adv Immunol. 1993, 54: 1-78.View ArticlePubMedGoogle Scholar
- Chen CC, Chen WC, Lu CH, Wang WH, Lin PY, Lee KD: Significance of interleukin-6 signaling in the resistance of pharyngeal cancer to irradiation and the epidermal growth factor receptor inhibitor. Int J Radiat Oncol Biol Phys. 2010, 76: 1214-24. 10.1016/j.ijrobp.2009.09.059View ArticlePubMedGoogle Scholar
- Santer FR, Malinowska K, Culig Z, Cavarretta IT: Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells. Endocr Relat Cancer. 2010, 17: 241-53. 10.1677/ERC-09-0200PubMed CentralView ArticlePubMedGoogle Scholar
- George DJ, Halabi S, Shepard TF, Sanford B, Vogelzang NJ, Small EJ: The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480. Clin Cancer Res. 2005, 11: 1815-20. 10.1158/1078-0432.CCR-04-1560View ArticlePubMedGoogle Scholar
- Oka M, Yamamoto K, Takahashi M, Hakozaki M, Abe T, Iizuka N: Relationship between serum levels of interleukin 6, various disease parameters and malnutrition in patients with esophageal squamous cell carcinoma. Cancer Res. 1996, 56: 2776-80.PubMedGoogle Scholar
- Scambia G, Testa U, Benedetti Panici P, Foti E, Martucci R, Gadducci A: Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br J Cancer. 1995, 71: 354-6. 10.1038/bjc.1995.71PubMed CentralView ArticlePubMedGoogle Scholar
- Kim DK, Oh SY, Kwon HC, Lee S, Kwon KA, Kim BG: Clinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer. BMC Cancer. 2009, 9: 155. 10.1186/1471-2407-9-155PubMed CentralView ArticlePubMedGoogle Scholar
- Lukaszewicz-Zajac M, Mroczko B, Kozlowski M, Niklinski J, Laudanski J, Szmitkowski M: Higher importance of interleukin 6 than classic tumor markers (carcinoembryonic antigen and squamous cell cancer antigen) in the diagnosis of esophageal cancer patients. Dis Esophagus. 2012, 25: 242-9. 10.1111/j.1442-2050.2011.01242.xView ArticlePubMedGoogle Scholar
- Rohatgi PR, Swisher SG, Correa AM, Wu TT, Liao Z, Komaki R: Histologic subtypes as determinants of outcome in esophageal carcinoma patients with pathologic complete response after preoperative chemoradiotherapy. Cancer. 2006, 106: 552-8. 10.1002/cncr.21601View ArticlePubMedGoogle Scholar
- Lee CH, Wu DC, Lee JM, Wu IC, Goan YG, Kao EL: Anatomical subsite discrepancy in relation to the impact of the consumption of alcohol, tobacco and betel quid on esophageal cancer. Int J Cancer. 2007, 120: 1755-62. 10.1002/ijc.22324View ArticlePubMedGoogle Scholar
- McConkey DJ, Choi W, Marquis L, Martin F, Williams MB, Shah J: Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer Metastasis Rev. 2009, 28: 335-44. 10.1007/s10555-009-9194-7View ArticlePubMedGoogle Scholar
- Bromberg J: Stat proteins and oncogenesis. J Clin Invest. 2002, 109: 1139-42.PubMed CentralView ArticlePubMedGoogle Scholar
- Chen MF, Lu MS, Lin PY, Chen PT, Chen WC, Lee KD: The role of DNA methyltransferase 3b in esophageal squamous cell carcinoma. Cancer. 2012, 118: 4074-89. 10.1002/cncr.26736View ArticlePubMedGoogle Scholar
- Tartour E, Pere H, Maillere B, Terme M, Merillon N, Taieb J: Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Rev. 2011, 30: 83-95. 10.1007/s10555-011-9281-4View ArticlePubMedGoogle Scholar
- Sharma S, Sharma MC, Sarkar C: Morphology of angiogenesis in human cancer: a conceptual overview, histoprognostic perspective and significance of neoangiogenesis. Histopathology. 2005, 46: 481-9. 10.1111/j.1365-2559.2005.02142.xView ArticlePubMedGoogle Scholar
- Kuonen F, Secondini C, Ruegg C, : Emerging pathways mediating growth, invasion and metastasis of tumors progressing in an irradiated microenvironment. Clin Cancer Res. 2012, 18: 5196-202. 10.1158/1078-0432.CCR-11-1758View ArticlePubMedGoogle Scholar
- Stahl M: Is there any role for surgery in the multidisciplinary treatment of esophageal cancer?. Ann Oncol. 2010, 21 (Suppl 7): vii283-5.PubMedGoogle Scholar
- Guo Y, Xu F, Lu T, Duan Z, Zhang Z: Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev. 2012, 38: 904-10. 10.1016/j.ctrv.2012.04.007View ArticlePubMedGoogle Scholar
- Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003, 22: 7265-79. 10.1038/sj.onc.1206933View ArticlePubMedGoogle Scholar
- Suchi K, Fujiwara H, Okamura S, Okamura H, Umehara S, Todo M: Overexpression of Interleukin-6 suppresses cisplatin-induced cytotoxicity in esophageal squamous cell carcinoma cells. Anticancer Res. 2011, 31: 67-75.PubMedGoogle Scholar
- Trikha M, Corringham R, Klein B, Rossi JF: Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res. 2003, 9: 4653-65.PubMed CentralPubMedGoogle Scholar
- Leu CM, Wong FH, Chang C, Huang SF, Hu CP: Interleukin-6 acts as an antiapoptotic factor in human esophageal carcinoma cells through the activation of both STAT3 and mitogen-activated protein kinase pathways. Oncogene. 2003, 22: 7809-18. 10.1038/sj.onc.1207084View ArticlePubMedGoogle Scholar
- Chen MF, Lee KD, Lu MS, Chen CC, Hsieh MJ, Liu YH: The predictive role of E2-EPF ubiquitin carrier protein in esophageal squamous cell carcinoma. J Mol Med (Berl). 2009, 87: 307-20. 10.1007/s00109-008-0430-3.View ArticleGoogle Scholar
- Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002, 2: 442-54. 10.1038/nrc822View ArticlePubMedGoogle Scholar
- Gotzmann J, Mikula M, Eger A, Schulte-Hermann R, Foisner R, Beug H: Molecular aspects of epithelial cell plasticity: implications for local tumor invasion and metastasis. Mutat Res. 2004, 566: 9-20. 10.1016/S1383-5742(03)00033-4View ArticlePubMedGoogle Scholar
- Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C: Stat3 as an oncogene. Cell. 1999, 98: 295-303. 10.1016/S0092-8674(00)81959-5View ArticlePubMedGoogle Scholar
- Levy DE, Darnell JE: Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol. 2002, 3: 651-62.View ArticlePubMedGoogle Scholar
- Schindler C, Levy DE, Decker T: JAK-STAT signaling: from interferons to cytokines. J Biol Chem. 2007, 282: 20059-63. 10.1074/jbc.R700016200View ArticlePubMedGoogle Scholar
- Aggarwal BB A, Kunnumakkara AB, Harikumar KB, Gupta SR, Tharakan ST, Koca C: Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship?. Ann N Y Acad Sci. 2009, 1171: 59-76. 10.1111/j.1749-6632.2009.04911.xPubMed CentralView ArticlePubMedGoogle Scholar
- Brown JM, Attardi LD: The role of apoptosis in cancer development and treatment response. Nat Rev Cancer. 2005, 5: 231-7. 10.1038/nrc1560PubMedGoogle Scholar
- Olive PL, Banath JP: Phosphorylation of histone H2AX as a measure of radiosensitivity. Int J Radiat Oncol Biol Phys. 2004, 58: 331-5. 10.1016/j.ijrobp.2003.09.028View ArticlePubMedGoogle Scholar
- Oshima Y, Yajima S, Yamazaki K, Matsushita K, Tagawa M, Shimada H: Angiogenesis-related factors are molecular targets for diagnosis and treatment of patients with esophageal carcinoma. Ann Thorac Cardiovasc Surg. 2010, 16: 389-93.PubMedGoogle Scholar
- Kozin SV, Duda DG, Munn LL, Jain RK: Neovascularization after irradiation: what is the source of newly formed vessels in recurring tumors?. J Natl Cancer Inst. 2012, 104: 899-905. 10.1093/jnci/djs239PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.